$2.69
MEI Pharma
Performance
Dividends
0%
1W
1M
YTD
1Y
3Y
11/36
Growth Score
13/36
Dividend Score
Valuation
PE Ratio
-0.57
PS Ratio
0
RSI
-
PEG Ratio
-0.03
PRG Ratio
0
0
PDG Ratio
0
Growth
20%34%300%0%
42%156%341%358%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
Rule of 40
0%
Gross Margin
0%
3
Current Ratio
16.78
Return on Assets
-152.38%
0
Return on Equity
-127.24%
0
Return on inv. Capital
-171.73%
Institutional Holder
3.368.04103.405.505
13317
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 65.30M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 17.78M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 64.91M
2018
2019
2020
2021
2022
2023
2024
6
Events
MEIP
MEI Pharma
in 295 days
[missing "en-US.common.--" translation]
Earnings per Share is expected with - and revenue with - .
MEIP
MEI Pharma
in 205 days
[missing "en-US.common.--" translation]
Earnings per Share is expected with - and revenue with - .
MEIP
MEI Pharma
in 113 days
[missing "en-US.common.--" translation]
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
18.12.2003
MaketCap
17.92M
Country
US
CEO
Justin J. File CPA
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Updated 12.07.2025